Skip to main content
Premium Trial:

Request an Annual Quote

Dutch VC Shop Invests $2.7M in Jurilab to Help Drive Metabolic Syndrome Research

NEW YORK (GenomeWeb News) — DSM Venturing has invested €2 million ($2.7 million) in Finnish diagnostics company Jurilab, DSM said today.
Jurilab specializes in disease markers and pathways, drug targets, and diagnostic content for metabolic syndrome. DSM, a financing branch of the Dutch company Royal DSM, said it believes that Jurilab’s access to the “relatively homogenous” East Finland founder population and its databank make its approach “faster, more informative, and more cost-effective than many traditional screening approaches."
Metabolic syndrome is sometimes used as an umbrella term to cover obesity, type 2 diabetes, dyslipidemia, and hypertension, DSM said. The market for diagnostics and personalized approaches to these diseases will continue to grow as populations age and become more health conscious, DSM said.
DSM last year put $2.6 million into its nutrigenomics programs through an investment in molecular diagnostics company Integragen.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.